1. Home
  2. CAPR

CAPR

Capricor Therapeutics Inc.

Logo Capricor Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Founded: 2005 Country:
United States
United States
Employees: 102 City: BEVERLY HILLS
Market Cap: 196.3M IPO Year: N/A
Target Price: $24.00 AVG Volume (30 days): 270.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.83 EPS Growth: N/A
52 Week Low/High: $2.68 - $8.22 Next Earning Date: 05-09-2024
Revenue: $25,178,066 Revenue Growth: 886.81%
Revenue Growth (this year): 15.59% Revenue Growth (next year): 318.29%

Share on Social Networks: